HIM
BPMC

Hillsdale Investment Management’s Blueprint Medicines BPMC Stock Holding History

Hillsdale Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,000
Closed -$8.08M – 651
2025
Q2 		$8.08M Buy
63,000
+10,600
+20% +$1.1M 0.3% 49
2025
Q1 		$4.64M Buy
52,400
+1,570
+3% +$153K 0.24% 78
2024
Q4 		$4.43M Buy
50,830
+310
+0.6% +$28.4K 0.22% 106
2024
Q3 		$4.67M Buy
50,520
+250
+0.5% +$24.8K 0.36% 77
2024
Q2 		$5.42M Sell
50,270
-3,200
-6% -$320K 0.43% 52
2024
Q1 		$5.07M Buy
+53,470
New +$4.59M 0.4% 69
2021
Q2 		– Sell
-9,000
Closed -$875K – 578
2021
Q1 		$875K Buy
+9,000
New +$899K 0.07% 267

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hillsdale Investment Management's BPMC Position: Q3 2025 in Review

Hillsdale Investment Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 63,000 shares — an estimated $8.08M sold.

Hillsdale Investment Management first reported a position in BPMC in Q1 2021 and held it in 7 quarters. The position peaked at $8.08M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Hillsdale Investment Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 63,000 Blueprint Medicines shares in Q3 2025, an estimated $8.08M.
  • Hillsdale Investment Management first reported a position in Blueprint Medicines in Q1 2021 and held it in 7 quarters.
  • Hillsdale Investment Management's Blueprint Medicines position peaked at $8.08M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Hillsdale Investment Management's 13F filing for Q3 2025, filed 10 Nov 2025.